menu

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment 

4 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life. 

    In this educational activity, expert faculty will review the role of genetic testing in identifying patients likely to benefit from first-line maintenance PARP inhibitor therapy, such as those with BRCA1/2 pathologic variants and other causes of homologous recombination deficiency (HRD) positivity; updated clinical data surrounding PARP inhibitors as first-line maintenance therapy; and how the earlier introduction of PARP inhibitors fits in the treatment paradigm of ovarian cancer and may benefit a greater number of patients than in the relapsed setting. 

    Chapters: 

    1. What Is Cytogenetic Testing and Why Should I Use It? Identification of Patients Who Might Benefit from PARP Inhibitor Therapy 
    1. Where Do PARP Inhibitors Fit in the Treatment Paradigm of Ovarian Cancer? Practical Strategies 
    1. Clinical Data for PARP Inhibitors as Maintenance Therapy for Newly-Diagnosed Advanced Ovarian Cancer 
    1. PARP Inhibitors as Maintenance Therapy and Treatment for Relapsed/Recurrent Advanced Ovarian Cancer 
  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose allpersonalfinancialrelationships they mayhave in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.  

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

    The faculty reported the following relevant financial relationshipsor relationshipsthey havewith ineligible companies of any amount during the past 24 months: 

    Kathleen N. Moore, MD, MS, reported a financial interest/relationship or affiliation in the form of Advisor; AstraZeneca Pharmaceuticals LP, Aadi, Blueprint Pharma, Clovis Oncology, Caris, Eisai Inc., Duality, GlaxoSmithKline, Genentech/Roche, ImmunoGen, Lilly USA, Mereo, Merck & Co., Inc., Mersana, Myriad Genetics, Inc., Novartis Pharmaceuticals, Corporation, OncXerna, Onconova Therapeutics, Inc., Pannavance, Regeneron Pharmaceuticals, Inc., VBL Therapeutics, Verastem Inc., Zentalis. Research grant; PTC Therapeutics, Lilly USA, GlaxoSmithKline, Genentech, Inc., Verastem Inc. Received income in any amount from; GOG Partners. 

    The directors, planners, managers, and peer reviewers and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Joseph Kim, MD; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to: 

    • Utilize molecular profiling to guide treatment selection for first-line maintenance therapy with PARP inhibitors 
    • Incorporate PARP inhibitors into treatment plans for first-line maintenance therapy of advanced ovarian cancer based on updated clinical data, guideline recommendations, and patient- and disease-related features 
    • Integrate early consultation to gynecologic oncologists for molecular profiling, patient selection, and communication of evidence-based treatment selection for first-line maintenance treatment of advanced ovarian cancer with PARP inhibitors 
    • Summarize the latest evidence supporting FDA revisions and clinical practice guideline implications regarding the role of PARP inhibitors in patients with recurrent ovarian cancer 
  • Target Audience

    This educational activity is designed for gynecologic oncologists, medical oncologists, gynecologists, advanced healthcare practitioners, nurses, pharmacists, pathologists, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with ovarian cancer. 

  • Accreditation and Credit Designation Statements

    Accrediation Statement

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis, LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

    Credit Designation for Physicians 
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     

    Credit Designation for Physician Assistants 

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until. 2/27/2025. PAs should only claim credit commensurate with the extent of their participation. 

     

    Credit Designation for Pharmacists 
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-9999-24-010-H01-P. 

     

    Credit Designation for Nursing 
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour. Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

     

    Laboratory Professionals 
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program. 

  • Jointly Provided by

    Jointly provided by  

  • Commercial Support

    This educational activity is supported by educational grants from GSK, Merck Sharp & Dohme LLC, and AstraZeneca Pharmaceuticals. 

  • Disclaimer

    Disclosure of Unlabeled Use                                       
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information. 

    Disclaimer           
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The establishment of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as an effective therapeutic strategy in ovarian cancer has been made possible through a deepened understanding of the impact of mutations in DNA damage response pathways on tumorigenesis. The success of this approach has led to the regulatory approval of PARP inhibitors for the treatment of patients with advanced ovarian cancer. PARP inhibitors as first-line maintenance therapy demonstrate a substantial and clinically meaningful benefit in progression-free survival among patients with newly diagnosed advanced ovarian cancer, including BRCA-mutated and HRD-positive disease. In some cases, regulatory approvals of PARP inhibitors have brought approvals for companion diagnostics or complementary diagnostic tests. Together, these developments have yielded a wealth of new options for managing ovarian cancer but have also complicated the effectiveness of the multidisciplinary care team, which is essential for the highest standard of cancer care delivery, linking emerging treatments and guidelines with patient education and empowerment. Another vital component of ovarian cancer care is the use of shared decision-making and patient-reported outcomes to increase patient satisfaction, therapy adherence, and quality of life. 

    In this educational activity, expert faculty will review the role of genetic testing in identifying patients likely to benefit from first-line maintenance PARP inhibitor therapy, such as those with BRCA1/2 pathologic variants and other causes of homologous recombination deficiency (HRD) positivity; updated clinical data surrounding PARP inhibitors as first-line maintenance therapy; and how the earlier introduction of PARP inhibitors fits in the treatment paradigm of ovarian cancer and may benefit a greater number of patients than in the relapsed setting. 

    Chapters: 

    1. What Is Cytogenetic Testing and Why Should I Use It? Identification of Patients Who Might Benefit from PARP Inhibitor Therapy 
    1. Where Do PARP Inhibitors Fit in the Treatment Paradigm of Ovarian Cancer? Practical Strategies 
    1. Clinical Data for PARP Inhibitors as Maintenance Therapy for Newly-Diagnosed Advanced Ovarian Cancer 
    1. PARP Inhibitors as Maintenance Therapy and Treatment for Relapsed/Recurrent Advanced Ovarian Cancer 
  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose allpersonalfinancialrelationships they mayhave in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.  

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

    The faculty reported the following relevant financial relationshipsor relationshipsthey havewith ineligible companies of any amount during the past 24 months: 

    Kathleen N. Moore, MD, MS, reported a financial interest/relationship or affiliation in the form of Advisor; AstraZeneca Pharmaceuticals LP, Aadi, Blueprint Pharma, Clovis Oncology, Caris, Eisai Inc., Duality, GlaxoSmithKline, Genentech/Roche, ImmunoGen, Lilly USA, Mereo, Merck & Co., Inc., Mersana, Myriad Genetics, Inc., Novartis Pharmaceuticals, Corporation, OncXerna, Onconova Therapeutics, Inc., Pannavance, Regeneron Pharmaceuticals, Inc., VBL Therapeutics, Verastem Inc., Zentalis. Research grant; PTC Therapeutics, Lilly USA, GlaxoSmithKline, Genentech, Inc., Verastem Inc. Received income in any amount from; GOG Partners. 

    The directors, planners, managers, and peer reviewers and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Joseph Kim, MD; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to: 

    • Utilize molecular profiling to guide treatment selection for first-line maintenance therapy with PARP inhibitors 
    • Incorporate PARP inhibitors into treatment plans for first-line maintenance therapy of advanced ovarian cancer based on updated clinical data, guideline recommendations, and patient- and disease-related features 
    • Integrate early consultation to gynecologic oncologists for molecular profiling, patient selection, and communication of evidence-based treatment selection for first-line maintenance treatment of advanced ovarian cancer with PARP inhibitors 
    • Summarize the latest evidence supporting FDA revisions and clinical practice guideline implications regarding the role of PARP inhibitors in patients with recurrent ovarian cancer 
  • Target Audience

    This educational activity is designed for gynecologic oncologists, medical oncologists, gynecologists, advanced healthcare practitioners, nurses, pharmacists, pathologists, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with ovarian cancer. 

  • Accreditation and Credit Designation Statements

    Accrediation Statement

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis, LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

    Credit Designation for Physicians 
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     

    Credit Designation for Physician Assistants 

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until. 2/27/2025. PAs should only claim credit commensurate with the extent of their participation. 

     

    Credit Designation for Pharmacists 
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-9999-24-010-H01-P. 

     

    Credit Designation for Nursing 
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour. Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

     

    Laboratory Professionals 
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program. 

  • Jointly Provided by

    Jointly provided by  

  • Commercial Support

    This educational activity is supported by educational grants from GSK, Merck Sharp & Dohme LLC, and AstraZeneca Pharmaceuticals. 

  • Disclaimer

    Disclosure of Unlabeled Use                                       
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information. 

    Disclaimer           
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule14 Apr 2024